Insider Selling: Autolus Therapeutics (NASDAQ:AUTL) Insider Sells $15,708.42 in Stock

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) insider Cintia Piccina sold 6,713 shares of Autolus Therapeutics stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $2.34, for a total value of $15,708.42. Following the completion of the transaction, the insider owned 13,287 shares in the company, valued at $31,091.58. The trade was a 33.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Autolus Therapeutics Stock Down 2.2%

Shares of Autolus Therapeutics stock opened at $2.24 on Friday. Autolus Therapeutics PLC Sponsored ADR has a 12-month low of $1.17 and a 12-month high of $2.58. The firm has a market capitalization of $596.20 million, a PE ratio of -2.11 and a beta of 2.10. The company has a quick ratio of 4.40, a current ratio of 4.89 and a debt-to-equity ratio of 1.04. The stock’s fifty day moving average is $1.88 and its 200-day moving average is $1.67.

Autolus Therapeutics (NASDAQ:AUTL) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.06. The business had revenue of $45.69 million during the quarter, compared to analyst estimates of $38.56 million. Autolus Therapeutics had a negative return on equity of 178.66% and a negative net margin of 238.66%. Equities analysts anticipate that Autolus Therapeutics PLC Sponsored ADR will post -0.75 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have commented on AUTL. Weiss Ratings upgraded shares of Autolus Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 13th. HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Autolus Therapeutics in a report on Monday, August 3rd. Finally, Wall Street Zen upgraded shares of Autolus Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, August 16th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Autolus Therapeutics has an average rating of “Moderate Buy” and an average price target of $10.00.

Institutional Investors Weigh In On Autolus Therapeutics

Hedge funds have recently bought and sold shares of the business. Invesco Ltd. boosted its position in Autolus Therapeutics by 53.3% during the 1st quarter. Invesco Ltd. now owns 32,738 shares of the company’s stock worth $51,000 after acquiring an additional 11,381 shares during the period. Jane Street Group LLC increased its holdings in shares of Autolus Therapeutics by 809.4% in the 1st quarter. Jane Street Group LLC now owns 102,493 shares of the company’s stock valued at $159,000 after purchasing an additional 91,222 shares during the period. Geode Capital Management LLC increased its holdings in shares of Autolus Therapeutics by 90.5% in the 2nd quarter. Geode Capital Management LLC now owns 164,314 shares of the company’s stock valued at $375,000 after purchasing an additional 78,058 shares during the period. The Manufacturers Life Insurance Company lifted its position in shares of Autolus Therapeutics by 41.6% in the second quarter. The Manufacturers Life Insurance Company now owns 38,419 shares of the company’s stock worth $88,000 after purchasing an additional 11,289 shares in the last quarter. Finally, Bank of America Corp DE lifted its position in shares of Autolus Therapeutics by 2,891.7% in the second quarter. Bank of America Corp DE now owns 975,135 shares of the company’s stock worth $2,223,000 after purchasing an additional 942,540 shares in the last quarter. 72.83% of the stock is owned by hedge funds and other institutional investors.

Autolus Therapeutics Company Profile

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.